quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:05:00·8d
PRRelease
Harmony Biosciences Holdings Inc. logo

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

HRMY· Harmony Biosciences Holdings Inc.
Health Care
Original source

Companies

  • HRMY
    Harmony Biosciences Holdings Inc.
    Health Care

Recent analyst ratings

  • Feb 23UpdateDeutsche Bank-
  • Feb 23UpdateTruist-
  • Feb 11UpdateUBS$46.00
  • Jul 21UpdateTruist$48.00
  • Jul 10UpdateGoldman$33.00
  • Jun 2UpdateOppenheimer$61.00

Related

  • PR1d
    Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
  • SEC10d
    Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR10d
    Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
  • INSIDER14d
    SEC Form 4 filed by Zaeske Adam H.
  • INSIDER17d
    SEC Form 4 filed by Anastasiou Peter
  • INSIDER17d
    SEC Form 4 filed by Ignelzi Troy A.
  • INSIDER17d
    SEC Form 3 filed by new insider Ignelzi Troy A.
  • SEC21d
    SEC Form DEFA14A filed by Harmony Biosciences Holdings Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022